Healthcare / Drug Manufacturers - Specialty & GenericTaipei Exchange
$18.00
+0.50 (+2.86%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 16%
FCF escenarios
weak_data · normalized FCF $5.9M · quality 33.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
16/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.0B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-3.4%
↓Gross Margin
35.6%
↓Debt/Equity
0.74
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-0.9%
FCF CAGR
-52.3%
FCF margin
0.7%
FCF / Net income
-0.17x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $843.3M · net income $-34.1M · FCF $5.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $843.3M | $843.3M | $895.3M | $939.9M | $866.3M |
| Net Income | $-34.1M | $-34.1M | $-57.2M | $21.9M | $-12.6M |
| EBITDA | $47.2M | $47.2M | $33.4M | $131.3M | $84.7M |
| EPS | — | — | -1.03 | 0.42 | -0.26 |
| Gross Margin | 35.6% | 35.6% | 36.4% | 42.2% | 38.3% |
| Operating Margin | -5.1% | -5.1% | -6.3% | 5.7% | 0.7% |
| Net Margin | -4.0% | -4.0% | -6.4% | 2.3% | -1.4% |
| Balance Sheet | |||||
| Debt/Equity | 0.74 | 0.74 | 0.71 | 0.72 | 1.23 |
| Current Ratio | 1.57 | 1.57 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $5.9M | $5.9M | $51.4M | $-60.7M | $54.6M |
| Returns | |||||
| ROE | -3.4% | -3.4% | -5.6% | 2.0% | -1.7% |
| Valuation | |||||
| P/E | — | — | — | 115.24 | — |
| EV/EBITDA | — | — | 51.81 | 22.77 | 24.28 |
| P/B | — | — | 1.33 | 2.29 | 1.94 |
| Growth & Yield | |||||
| Revenue Growth | -5.8% | -5.8% | -4.7% | 8.5% | — |
| EPS Growth | — | — | -345.2% | 261.5% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+10.8%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.03 → n/d
Residual
+10.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.